Partners

Awardees and Affiliated Institutions

• AstraZeneca Pharmaceuticals, Waltham, MA
• Baylor College of Medicine, Houston, TX
• Brigham Young University, Provo, UT
• Bristol Myers Squibb, New York, NY
• Broad Institute of MIT and Harvard, Cambridge, MA
• Bruker Corporation, Billerica, MA
• Cell Signaling, Danvers, MA
• Cellenion, Lyon, France
• Dana-Farber Cancer Institute, Boston, MA
• ECOG-ACRIN, Philadelphia, PA
• Emory Winship Cancer Institute, Atlanta, GA
• Fred Hutchinson Cancer Research Center, Seattle, WA
• Icahn School of Medicine at Mount Sinai, New York, NY
• ICF, Rockville, MD
• Institute for Systems Biology, Seattle, WA
• Johns Hopkins University, Baltimore, MD
• Koch Institute for Integrative Cancer Research at MIT, Cambridge, MA
• Massachusetts General Hospital, Boston, MA
• Mayo Clinic Arizona, Scottsdale, AZ
• Mayo Clinic, Rochester, MN
• Melanoma Institute Australia, Wollstonecraft, Australia
• Memorial Sloan Kettering Cancer Center, New York, NY
• New York University Grossman School of Medicine, NY, NY
• Oregon Health & Science University, Portland, OR
• Pacific Northwest National Laboratory, Richland, WA
• Seven Bridges Genomics Inc, Charlestown, MA
• SISCAPA Assay Technologies, Washington, DC
• The Children's Hospital of Philadelphia, Philadelphia, PA
• The J. David Gladstone Institutes, San Francisco, CA
• The University of Texas MD Anderson Cancer Center, Houston, TX
• ThermoFisher Scientific, San Jose, CA
• University of California, Irvine, CA
• University of Massachusetts Boston, Boston, MA
• University of Miami, Miami, FL
• University of Michigan, Ann Arbor, MI
• University of Pennsylvania, Philadelphia, PA
• University of Pittsburgh, Pittsburgh, PA
• University of Texas Health Science Center at Houston, Houston, TX
• University of Washington, Seattle, WA
• Vanderbilt University Medical Center, Nashville, TN
• Washington University School of Medicine, St. Louis, MO
• Weill Cornell Medicine, New York, NY
• Yale University, New Haven, CT

Additional Partners

American Association for Clinical Chemistry
NCI’s OCCPR collaborates with the American Association for Clinical Chemistry (AACC) via a memorandum of understanding (MOU) to promote and educate the clinical chemistry community in the area of proteomic standards/technologies to further its application in clinical labs.

Food and Drug Administration
NCI’s OCCPR and the Food and Drug Administration (FDA) formally collaborate (through a memorandum of understanding - MOU) to accelerate the translations of proteomics technologies and applications into clinical settings. This collaborative partnership has facilitated the FDA to be involved in the Clinical Proteomic Tumor Analysis Consortium’s discovery and confirmatory analytical workflows in the following capacities:

• development of open access (mock 510K) regulatory science documents on proteomic technologies
  • Analytical Validation of Protein-Based Multiplex Assays: A Workshop Report by the NCI-FDA Interagency Oncology Task Force on Molecular Diagnostics
  • Protein-Based Multiplex Assays: Mock Presubmissions to the U.S. Food and Drug Administration
    • Mock 510(k) for a Multiplex Diagnostic Test using Immunoaffinity Mass Spectrometry Protein Quantitation.
    • Mock 510(k) for a An Immumological Array Platform for Simultaneous Assay of Multiple Glycoprotein Isoforms
• development of best practice [CLSI guidance] documents on the design, development, and validation of quantitative assays for targeted proteomic assays by mass spectrometry, and
• big data multiomics challenges

National Institute of Standards and Technology
NCI’s OCCPR collaborates with the National Institute of Standards and Technology (NIST) to develop mass spectrometry-based technology assessment quality control tools used by the CPTAC teams and the broad research community.

Uniprot
NCI’s OCCPR collaborates with UniProt, the leading online protein reference library. In addition to searching for a protein-of-interest in UniProt, which includes cross-reference links to the NCI CPTAC Assay Portal for fit-for-purpose targeted assays, users now have cross-reference links to the NCI CPTAC Antibody Portal for cancer-associated renewable antibodies.

NCI’s OCCPR has a long-standing collaboration with the Human Proteome Organization (HUPO) that is centered in promoting every step in the road towards translation of proteomic measurements to patient care, from accurate and reliable measurements, to clinical and analytical validation of biomarkers, to regulatory compliance.

Tissue Source Sites

• Audubon Biosciences
• Baylor College of Medicine
• BioCell Analytics, Inc.
• Children’s Hospital of Philadelphia
• Cureline, Inc.
• Duke University
• Fidelis Research
• H. Lee Moffitt Cancer Center and Research Institute
• Hackensack Meridian Health – Jersey Shore University Medical Center
• International Institute for Molecular Oncology
• Mayo Clinic Jacksonville
• Memorial Sloan Kettering Cancer Center
• Morehouse School of Medicine
• Phase Clinical Services
• ProteoGenex, Inc.
• Sinai Health System
• Spectrum Health System
• St. Joseph’s Hospital & Medical Center
• Thomas Jefferson University
• University of Calgary
• University of Kansas Medical Center
• University of Oklahoma
• University of Pittsburgh
• University of South Florida
• University of Texas El Paso
• University of Texas Health Science Center at San Antonio
• University of Texas Southwestern
• Washington University in St. Louis
• William Beaumont Hospital

Biospecimen Core Resource

• Van Andel Research Institute

Commercialization

CPTAC collaborates with industry through various mechanisms, including research proposals to be funded through the Small Business Innovation Research (SBIR) program. Find out more information on collaborative opportunities by contacting us at cancer.proteomics@mail.nih.gov